GlobeNewswire

Cority Unveils Enhanced Quality Management Solution on its True SaaS EHSQ Platform

Share

Solution streamlines shop floor processes, manages the entire nonconformance lifecycle, and supports enterprise-wide continuous improvement initiatives

TORONTO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Cority, the most trusted provider of environmental, health, safety, and quality (EHSQ) software, today announced the availability of its enhanced Quality Management solution. Designed to provide Quality professionals with a closed-loop continuous improvement process to ensure product safety, compliance and drive operational efficiency, Cority increases visibility across the supply chain to monitor suppliers, capture customer feedback, and ensure the highest product standards. This latest release shows Cority’s commitment to providing organizations with the most comprehensive, integrated EHSQ solution to support their operational and compliance needs.

“Many organizations still rely on paper-based processes to manage quality, which can result in outdated documents, siloed information, and missing approvals. Others are looking to bring Quality and EHS together under broader and more strategic operational programs,” said John Easton, VP Product Management, Cority. “To ensure our clients can proactively manage risk within their facilities, support ISO 9001 requirements, and enable integrated EHSQ, we’ve developed a complete nonconformance lifecycle on the Cority Platform that initiates investigations, root cause analysis, corrective actions and preventive actions (CAPAs) as well as management of change to enable a closed-loop continuous improvement process.”

Key capabilities of Cority’s Quality Management solution include:

Nonconformances – streamline the nonconformance lifecycle process to resolve deviation recurrence and support regulatory requirements

Management of Change - review and manage all proposed changes to equipment, raw materials, processes, personnel and procedures to ensure risks are controlled

Document Control – easily manage and distribute documents for review and approval to maintain industry and regulatory compliance requirements in the event of an audit

Audits – manage internal and supplier audits to ensure quality processes, procedures, and systems are compliant with regulatory and industry requirements

Supplier Management – onboard and manage suppliers, documentation, and ensure compliance with suppliers and contract vendors

Complaint Management – track customer complaints through the nonconformance lifecycle to determine the root cause, resolve issues and reduce product deviations

Equipment and Maintenance – proactively manage equipment maintenance and calibration records to comply with quality standards and ensure product safety

Dashboards and Reporting – monitor quality KPIs and drill down into yield of products manufactured correctly, customer returns, and supplier quality to identify trends and address production issues

Integrated EHSQ on a True SaaS Platform – enables all EHSQ workflows and processes across the enterprise to be managed from a single solution with a consistent user interface  

While firms have historically run EHS and quality as indepen­dent functions, the industrial sector has made much progress in recent years towards the business integration of safety and quality. This transformation has been championed by business leaders that recognize the common objectives, challenges, and desired outcomes across EHS and Quality, eased by harmonization of relevant ISO standards, and streamlined by enterprise applications that provide robust integrated process automation,” said Dan Jacob, Principal Analyst and Research Director, LNS. “LNS Research data shows that those who have integrated EHS and Quality achieve significant operational and financial benefits. Operationally, integrated firms have a median of 87% more capabilities than those that have not, particularly in the adoption of cross-functional processes, automation of processes with software, and risk management. This more capable environment results in a median of 17% lower supplier defect rates, lower cost of poor quality translating to roughly 7% higher operating margins, and a higher percentage of products in compliance.”

To learn more about Cority’s Quality Management Solution, visit https://www.cority.com/ehsq-software/quality/

About Cority
Cority is the most trusted environmental, health, safety, and quality (EHSQ) software for assuring client success. Cority enables organizations to utilize EHSQ software to advance their journey to sustainability and operational excellence by combining the deepest domain expertise with the most comprehensive and secure true SaaS platform. With 30+ years of innovation and experience, Cority’s team of over 350 experts serve more than 800 clients in 100 countries, supporting 2.5 million end users. The company enjoys the industry’s highest levels of client satisfaction and has received many awards for its strong employee culture and outstanding business performance.

Cority Software
media@cority.com

A video accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/31b6278f-1538-4df5-ace6-e35447733b50

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPress release

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED19.7.2019 12:00:00 CESTPress release

Rapala VMC Corporation Half year financial report July 19, 2019 at 1:00 p.m. RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED January-June (H1) in brief: Net sales were 141.2 MEUR, down 1% from previous year (142.5). With comparable exchange rates sales were 2% lower than last year. Operating profit was 11.4 MEUR (15.3), down 25%.1) Comparable operating profit* was 12.0 MEUR (15.2), down 21%. 1) Cash flow from operations was 11.5 MEUR (5.9). 2) Earnings per share was 0.17 EUR (0.23), down 26%. Full year guidance unchanged: Full year net sales with comparable FX rates expected to be around last year’s level and comparable operating profit* to increase from last year. Strong second half of the year expected: record strong order book in North America, improvements in Indonesian lure factory combined with rigorous management of fixed costs. Uncertainties and risks relate to US-China trade relations, global ec

Scientific Beta defends the role of the Size factor in multi-factor portfolios19.7.2019 11:32:00 CESTPress release

Scientific Beta defends the role of the Size factor in multi-factor portfolios Research shows that omitting the Size factor would be costly for investors New research from Scientific Beta, the smart beta index provider, has shown that the Size factor improves model fit, delivers a significant positive premium in the presence of other factors, and contributes positively to the performance of multi-factor portfolios. The Size effect is well established in the finance literature: stocks with smaller market capitalisation outperform large stocks over the long term. However, a common recommendation in the asset management industry is to remove Size from the factor menu, given its relatively weak post-publication performance. Scientific Beta's analysis differs from recent studies by smart beta providers in assessing the relevance of the Size factor. Rather than asking which factor has the best stand-alone performance, we ask what the marginal impact of the Size factor is when including it in